BioCentury
ARTICLE | Clinical News

Pomalyst pomalidomide regulatory update

April 13, 2015 7:00 AM UTC

Japan approved Pomalyst pomalidomide from Celgene to treat relapsed or refractory multiple myeloma (MM) in patients previously treated with Revlimid lenalidomide and Velcade bortezomib. Pomalidomide...